Amiselimod, a novel, more selective S1P1 receptor-modulating compound improved the clinical and histological score of colitis in a CD4+CD45RB+ T-lymphocyte adoptive transfer model by reducing the infiltration of Th1 and Th17 cells in the colonic mucosa. The gene discussed is CD4; the disease is colitis.